DCM
NVO

Davis Capital Management’s Novo Nordisk NVO Stock Holding History

Davis Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$6K Hold
168
– – 0.01% 207
2020
Q1 		$5K Buy
+168
New +$5K 0.01% 208

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return

Davis Capital Management's NVO Position: Q2 2020 in Review

Davis Capital Management held its Novo Nordisk (NVO) position steady in Q2 2020 at 168 shares worth $6K. The position accounts for 0.01% of the portfolio, ranked #207.

Davis Capital Management first reported a position in NVO in Q1 2020 and has held it in 2 quarters since. 660 funds tracked by Wall St. Rank hold NVO as of Q2 2020.

  • Davis Capital Management held 168 shares of Novo Nordisk worth $6K as of Q2 2020.
  • Davis Capital Management left its Novo Nordisk share count unchanged in Q2 2020.
  • Novo Nordisk made up 0.01% of Davis Capital Management's portfolio in Q2 2020, its #207 holding.
  • Davis Capital Management first reported a position in Novo Nordisk in Q1 2020 and has held it in 2 quarters since.
  • 660 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2020.

Based on Davis Capital Management's 13F filing for Q2 2020, filed 29 Jul 2020.